查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424092

鴉片類藥物引起的便秘市場、份額、規模、趨勢、行業分析報告：活性成分、處方類型、給藥途徑、分銷渠道、地區、細分市場預測，2024-2032

Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球鴉片類藥物引起的便秘市場規模預計將達到 39.3 億美元。 該研究報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

鴉片類藥物最常用於緩解疼痛，包括嗎啡、曲馬多和芬太尼。 零售商店和線上電子商務平台上止痛藥供應的增加對市場上鴉片類藥物的需求產生了積極影響，包括鴉片類藥物引起的便秘的巨大增長潛力。

製藥公司、政府和非政府組織不斷進行的宣傳活動對鴉片類藥物引起的便秘市場產生了積極影響。 例如，2023 年，製藥商 Salix Pharmaceuticals 與另外兩個非營利組織一起宣布 12 月 5 日為鴉片類藥物引起的便秘意識日，以消除圍繞這一問題的恥辱。

由於許多消費者越來越多地使用鴉片類藥物，預計對鴉片類藥物引起的便秘治療的需求將會增加。 現有數據表明，服用鴉片類藥物但未患癌症的人中，約有 40% 至 60% 患有鴉片類藥物引起的便秘 (OIC)。

與服用鴉片類藥物相關的便秘的高風險以及越來越多的研究考慮潛在原因和適當的治療方法正在擴大市場成長機會。 例如，國家醫學圖書館發表的一項研究調查了鴉片類藥物引起的便秘，並考慮了治療該疾病的潛在治療和非治療方法。

此外，鴉片類藥物的使用可能與癌症患者增加使用鴉片類藥物來緩解疼痛有關。 據製藥專家稱，大約 60% 至 90% 服用鴉片類藥物治療癌症的患者患有鴉片類藥物引起的便秘。 鴉片類藥物引起的便秘患者在日常生活活動中可能會面臨更多困難，尤其是那些面臨癌症疼痛的患者。

此外，研究工作正在積極影響為鴉片類藥物引起的便秘患者開發有效的治療方法。 例如，2024 年的一項研究重點在於確定鴉片類藥物引起的便秘與大鼠結腸叢中 P2Y1 受體之間的關係。

鴉片類藥物引起的便秘市場報告亮點

納洛昔醇類別預計將以最快的速度成長，因為它具有治療鴉片類藥物引起的便秘的潛力。

由於醫師諮詢的重要性日益增加，處方藥領域佔了最大份額。

口服藥物在市場上佔據主導地位，主要是因為治療攝取方便且療效高。

由於老年人口比例較大，亞太地區預計將出現最快的成長速度。

目錄

第 1 章簡介

第 2 章執行摘要

第 3 章研究方法

第 4 章洞察全球鴉片類藥物引起的便秘市場

  • 鴉片類藥物引起的便秘 - 行業快照
  • 鴉片類藥物引起的便秘市場動態
    • 促進因素和機會
      • 老年人的存在
      • 鴉片類藥物處方顯著增加
    • 抑制因素和挑戰
      • 減少市面上鴉片類藥物的使用
  • PESTLE分析
  • 鴉片類藥物引起的便秘產業趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第 5 章全球鴉片類藥物引起的便秘市場：依活性成分劃分

  • 主要發現
  • 簡介
  • 納洛昔康
  • 魯比前列酮
  • 溴化甲基納曲酮
  • 多庫酯鈉
  • 其他

第 6 章全球鴉片類藥物引起的便秘市場（依處方類型）

  • 主要發現
  • 簡介
  • 非處方藥
  • 處方、自然療法

第 7 章全球鴉片類藥物引起的便秘市場（依給藥途徑）

  • 主要發現
  • 簡介
  • 口服
  • 注射用
  • 其他

第 8 章全球鴉片類藥物引起的便秘市場（依通路）

  • 主要發現
  • 簡介
  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 9 章全球鴉片類藥物引起的便秘市場（按地區）

  • 主要發現
  • 簡介
    • 2019-2032 年鴉片類藥物引起的便秘市場評估，各地區
  • 鴉片類藥物引起的便秘市場 - 北美
    • 北美：2019-2032 年鴉片類藥物引起的便秘市場（依活性成分）
    • 北美：鴉片類藥物引起的便秘市場，依分銷管道劃分，2019-2032 年
    • 北美：2019-2032 年鴉片類藥物引起的便秘市場（依處方型）
    • 北美：鴉片類藥物引起的便秘市場，依給藥途徑劃分，2019-2032 年
    • 鴉片類藥物引起的便秘市場 - 美國
    • 鴉片類藥物引起的便秘市場 - 加拿大
  • 鴉片類藥物引起的便秘市場 - 歐洲
    • 歐洲：鴉片類藥物引起的便秘市場（依活性成分），2019-2032 年
    • 歐洲：鴉片類藥物引起的便秘市場，依分銷管道劃分，2019-2032 年
    • 歐洲：鴉片類藥物引起的便秘市場（依處方類型），2019-2032 年
    • 歐洲：鴉片類藥物引起的便秘市場，依給藥途徑劃分，2019-2032 年
    • 鴉片類藥物引起的便秘市場 - 英國
    • 鴉片類藥物引起的便秘市場 - 法國
    • 鴉片類藥物引起的便秘市場 - 德國
    • 鴉片類藥物引起的便秘市場 - 義大利
    • 鴉片類藥物引起的便秘市場 - 西班牙
    • 鴉片類藥物引起的便秘市場 - 荷蘭
    • 鴉片類藥物引起的便秘市場 - 俄羅斯
  • 鴉片類藥物引起的便秘市場 - 亞太地區
    • 亞太地區：2019-2032 年鴉片類藥物引起的便秘市場（依活性成分）
    • 亞太地區：鴉片類藥物引起的便秘市場，依通路劃分，2019-2032 年
    • 亞太地區：2019-2032 年鴉片類藥物引起的便秘市場（依處方類型）
    • 亞太地區：2019-2032 年鴉片類藥物引起的便秘市場（依給藥途徑）
    • 鴉片類藥物引起的便秘市場 - 中國
    • 鴉片類藥物引起的便秘市場 - 印度
    • 鴉片類藥物引起的便秘市場 - 日本
    • 鴉片類藥物引起的便秘市場 - 馬來西亞
    • 鴉片類藥物引起的便秘市場 - 印度尼西亞
    • 鴉片類藥物引起的便秘市場 - 韓國
  • 鴉片類藥物引起的便秘市場 - 中東和非洲
    • 中東和非洲：鴉片類藥物引起的便秘市場（按活性成分），2019-2032 年
    • 中東和非洲：鴉片類藥物引起的便秘市場，按分銷管道劃分，2019-2032 年
    • 中東和非洲：2019-2032 年鴉片類藥物引起的便秘市場（按處方類型）
    • 中東和非洲：2019-2032 年鴉片類藥物引起的便秘市場（依給藥途徑）
    • 鴉片類藥物引起的便秘市場 - 沙烏地阿拉伯
    • 鴉片類藥物引起的便秘市場 - 南非
    • 鴉片類藥物引起的便秘市場 - 以色列
    • 鴉片類藥物引起的便秘市場 - 阿拉伯聯合大公國
  • 鴉片類藥物引起的便秘市場 - 拉丁美洲
    • 拉丁美洲：鴉片類藥物引起的便秘市場（依活性成分），2019-2032 年
    • 拉丁美洲：鴉片類藥物引起的便秘市場，按分銷管道劃分，2019-2032 年
    • 拉丁美洲：2019-2032 年鴉片類藥物引起的便秘市場（以處方類型）
    • 拉丁美洲：2019-2032 年鴉片類藥物引起的便秘市場（依給藥途徑）
    • 鴉片類藥物引起的便秘市場 - 墨西哥
    • 鴉片類藥物引起的便秘市場 - 巴西
    • 鴉片類藥物引起的便秘市場 - 阿根廷

第 10 章競爭態勢

  • 擴張與收購分析
    • 擴大
    • 收購
  • 夥伴關係/協作/協議/揭露

第 11 章公司簡介

  • Abbott（US）
  • Aurobindo Pharma（India）
  • Bayer AG（Germany）
  • Boehringer Ingelheim International GmbH.（Germany）
  • Bristol Myers Squibb Company（US）
  • Cosmo Pharmaceuticals（Ireland）
  • Daewoong Pharmaceutical Company（South Korea）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Fresenius Kabi AG（Germany）
  • GSK Plc.（UK）
  • Hikma Pharmaceuticals PLC（UK）
  • Merck & Co Inc.（US）
  • Mylan NV（US）
  • Novartis AG（Switzerland）
  • Pfizer Inc（US）
Product Code: PM4344

The global opioid induced constipation market size is expected to reach USD 3.93 billion by 2032, according to a new study by Polaris Market Research. The report "Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Opioids are most used to get relief from pain, as they include morphine, tramadol, and fentanyl. The increased accessibility of painkillers at retail and online e-commerce platforms is showing a positive impact on the demand for opioids in the marketplace, including significant growth potential for opioid-induced constipation.

The rising awareness campaigns by pharmaceutical companies, governments, and non-government agencies are demonstrating a positive impact on the opioid-induced constipation market. For instance, in 2023, Salix Pharmaceuticals, a drug manufacturer, along with the other two non-profit organisations, declared December 5 as the opioid-induced constipation awareness day to confront the stigmas surrounding the issue.

The rising use of opioids among the larger consumer base is expected to boost demand for opioid-induced constipation treatment. According to the available data, among the individuals who consumed opioids without cancer, around 40-60% of the people get opioid-induced constipation (OIC).

The higher risk of constipation with the intake of opioid-related drugs, along with the growing research studies to review the potential causes and suitable treatments, are showing wider growth opportunities for the market. For instance, a study published in the National Library of Medicine explored opioid-induced constipation and reviewed potential therapeutic and non-therapeutic treatments to treat the disease.

Furthermore, the use of opioids can be related to the rising use by cancer patients to get pain relief. According to pharmaceutical experts, approximately 60 to 90% of patients who took the opioid for cancer treatment suffered from opioid-induced constipation. Opioid-induced constipation patients are likely to face more difficulties in day-to-day life activities, primarily those facing cancer pain.

Moreover, research activities are positively influencing the creation of effective treatments for patients suffering from opioid-induced constipation. For instance, a 2024 study focused on finding the relationship between opioid-induced constipation and the P2Y1 receptor in the colonic myenteric plexus of rats.

Opioid Induced Constipation Market Report Highlights

Naloxegol segment will grow at the fastest pace, due to its potential for treating opioid induced constipation issues.

Prescription segment held the largest share, owing to the rising importance of doctor consultation.

Oral segment dominated the market, primarily due to its ease of treatment intake and higher effectiveness.

Asia Pacific will register the fastest pace, attributable to the presence of the large proportion of elderly population.

The global players include Abbott, Aurobindo Pharma, Bayer, Boehringer Ingelheim International, & Bristol Myers Squibb Company.

Polaris Market Research has segmented the opioid induced constipation market report based on active ingredients, prescription type, route of administration, distribution channel and region:

Opioid Induced Constipation, Active Ingredients Outlook (Revenue - USD Billion, 2019 - 2032)

  • Naloxegol
  • Lubiprostone
  • Methylnaltrexone Bromide
  • Docusate Sodium
  • Others

Opioid Induced Constipation, Prescription Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Over The Counter Medicines
  • Prescription, Natural Remedies

Opioid Induced Constipation, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oral
  • Injectable
  • Others

Opioid Induced Constipation, Distribution Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Opioid Induced Constipation, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Opioid Induced Constipation Market Insights

  • 4.1. Opioid Induced Constipation - Industry Snapshot
  • 4.2. Opioid Induced Constipation Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The presence of an elderly population
      • 4.2.1.2. The significant rise in opioid prescriptions
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The declining use of opioids in the marketplace
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Opioid Induced Constipation Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Opioid Induced Constipation Market, by Active Ingredients

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • 5.3. Naloxegol
    • 5.3.1. Global Opioid Induced Constipation Market, by Naloxegol, by Region, 2019-2032 (USD Billion)
  • 5.4. Lubiprostone
    • 5.4.1. Global Opioid Induced Constipation Market, by Lubiprostone, by Region, 2019-2032 (USD Billion)
  • 5.5. Methylnaltrexone Bromide
    • 5.5.1. Global Opioid Induced Constipation Market, by Methylnaltrexone Bromide, by Region, 2019-2032 (USD Billion)
  • 5.6. Docusate Sodium
    • 5.6.1. Global Opioid Induced Constipation Market, by Docusate Sodium, by Region, 2019-2032 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Opioid Induced Constipation Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Opioid Induced Constipation Market, by Prescription Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • 6.3. Over The Counter Medicines
    • 6.3.1. Global Opioid Induced Constipation Market, by Over The Counter Medicines, by Region, 2019-2032 (USD Billion)
  • 6.4. Prescription, Natural Remedies
    • 6.4.1. Global Opioid Induced Constipation Market, by Prescription, Natural Remedies, by Region, 2019-2032 (USD Billion)

7. Global Opioid Induced Constipation Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Opioid Induced Constipation Market, by Oral, by Region, 2019-2032 (USD Billion)
  • 7.4. Parenteral
    • 7.4.1. Global Opioid Induced Constipation Market, by Parenteral, by Region, 2019-2032 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Opioid Induced Constipation Market, by Others, by Region, 2019-2032 (USD Billion)

8. Global Opioid Induced Constipation Market, by Distribution Channel

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 8.3. Hospital Pharmacy
    • 8.3.1. Global Opioid Induced Constipation Market, by Hospital Pharmacy, by Region, 2019-2032 (USD Billion)
  • 8.4. Online Pharmacy
    • 8.4.1. Global Opioid Induced Constipation Market, by Online Pharmacy, by Region, 2019-2032 (USD Billion)
  • 8.5. Retail Pharmacy
    • 8.5.1. Global Opioid Induced Constipation Market, by Retail Pharmacy, by Region, 2019-2032 (USD Billion)

9. Global Opioid Induced Constipation Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Opioid Induced Constipation Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Opioid Induced Constipation Market - North America
    • 9.3.1. North America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.3.2. North America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.3.3. North America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.3.4. North America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.5. Opioid Induced Constipation Market - U.S.
      • 9.3.5.1. U.S.: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.3.6. Opioid Induced Constipation Market - Canada
      • 9.3.6.1. Canada: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.4. Opioid Induced Constipation Market - Europe
    • 9.4.1. Europe: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.5. Opioid Induced Constipation Market - UK
      • 9.4.5.1. UK: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.6. Opioid Induced Constipation Market - France
      • 9.4.6.1. France: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.7. Opioid Induced Constipation Market - Germany
      • 9.4.7.1. Germany: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.8. Opioid Induced Constipation Market - Italy
      • 9.4.8.1. Italy: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.9. Opioid Induced Constipation Market - Spain
      • 9.4.9.1. Spain: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.10. Opioid Induced Constipation Market - Netherlands
      • 9.4.10.1. Netherlands: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.4.11. Opioid Induced Constipation Market - Russia
      • 9.4.11.1. Russia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.5. Opioid Induced Constipation Market - Asia Pacific
    • 9.5.1. Asia Pacific: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.5. Opioid Induced Constipation Market - China
      • 9.5.5.1. China: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.6. Opioid Induced Constipation Market - India
      • 9.5.6.1. India: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.7. Opioid Induced Constipation Market - Japan
      • 9.5.7.1. Japan: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.8. Opioid Induced Constipation Market - Malaysia
      • 9.5.8.1. Malaysia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.9. Opioid Induced Constipation Market - Indonesia
      • 9.5.9.1. Indonesia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.5.10. Opioid Induced Constipation Market - South Korea
      • 9.5.10.1. South Korea: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.6. Opioid Induced Constipation Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.5. Opioid Induced Constipation Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.6. Opioid Induced Constipation Market - South Africa
      • 9.6.6.1. South Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.7. Opioid Induced Constipation Market - Israel
      • 9.6.7.1. Israel: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.6.8. Opioid Induced Constipation Market - UAE
      • 9.6.8.1. UAE: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • 9.7. Opioid Induced Constipation Market - Latin America
    • 9.7.1. Latin America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.5. Opioid Induced Constipation Market - Mexico
      • 9.7.5.1. Mexico: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.6. Opioid Induced Constipation Market - Brazil
      • 9.7.6.1. Brazil: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
    • 9.7.7. Opioid Induced Constipation Market - Argentina
      • 9.7.7.1. Argentina: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Abbott (US)
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Aurobindo Pharma (India)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Bayer AG (Germany)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Boehringer Ingelheim International GmbH. (Germany)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Bristol Myers Squibb Company (US)
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Cosmo Pharmaceuticals (Ireland)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Daewoong Pharmaceutical Company (South Korea)
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. F. Hoffmann-La Roche Ltd (Switzerland)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Fresenius Kabi AG (Germany)
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. GSK Plc. (UK)
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Hikma Pharmaceuticals PLC (UK)
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Merck & Co Inc. (US)
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Mylan NV (US)
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Novartis AG (Switzerland)
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Pfizer Inc (US)
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development

List of Tables

  • Table 1 Global Opioid Induced Constipation Market, by Active Ingredients, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Opioid Induced Constipation Market, by Prescription Type, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Opioid Induced Constipation Market, by Route of Administration, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Opioid Induced Constipation Market, by Distribution Channel, by Region, 2019-2032 (USD Billion)
  • Table 5 Opioid Induced Constipation Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 7 North America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 8 North America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 9 North America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 10 U.S.: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 11 U.S.: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 12 U.S.: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 13 U.S.: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Canada: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 15 Canada: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 16 Canada: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 Canada: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 18 Europe: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 19 Europe: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 20 Europe: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 21 Europe: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 22 Germany: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 23 Germany: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 25 Germany: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 France: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 27 France: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 28 France: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 France: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 30 UK: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 31 UK: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 32 UK: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 33 UK: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 34 Italy: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 35 Italy: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 36 Italy: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 37 Italy: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 42 Spain: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 43 Spain: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 44 Spain: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 45 Spain: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 46 Russia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 47 Russia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 48 Russia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 49 Russia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 54 China: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 55 China: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 56 China: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 57 China: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 58 Japan: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 59 Japan: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 60 Japan: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 61 Japan: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 India: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 63 India: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 64 India: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 65 India: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 South Korea: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 75 South Korea: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 76 South Korea: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 77 South Korea: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 78 Latin America: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 79 Latin America: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 80 Latin America: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 81 Latin America: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 82 Brazil: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 83 Brazil: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 84 Brazil: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 85 Brazil: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 86 Mexico: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 87 Mexico: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 88 Mexico: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 89 Mexico: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 90 Argentina: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 91 Argentina: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 92 Argentina: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 93 Argentina: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 98 UAE: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 99 UAE: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 100 UAE: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 101 UAE: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 106 South Africa: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 107 South Africa: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 108 South Africa: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 109 South Africa: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 110 Israel: Opioid Induced Constipation Market, by Active Ingredients, 2019-2032 (USD Billion)
  • Table 111 Israel: Opioid Induced Constipation Market, by Prescription Type, 2019-2032 (USD Billion)
  • Table 112 Israel: Opioid Induced Constipation Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 113 Israel: Opioid Induced Constipation Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Opioid Induced Constipation Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Active Ingredients
  • Figure 7. Global Opioid Induced Constipation Market, by Active Ingredients, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Opioid Induced Constipation Market, by Distribution Channel, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Prescription Type
  • Figure 11. Global Opioid Induced Constipation Market, by Prescription Type, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Route of Administration
  • Figure 13. Global Opioid Induced Constipation Market, by Route of Administration, 2021 & 2030 (USD Billion)